Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Atea Pharmaceuticals Inc
(NQ:
AVIR
)
3.375
+0.005 (+0.15%)
Streaming Delayed Price
Updated: 1:01 PM EDT, Jun 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Atea Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
Next >
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 05, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
May 30, 2023
Gainers QualTek Services Inc. (NASDAQ: QTEK) shares jumped 127.2% to $0.1740 after dropping around 21% on Friday. Qualtek Services recently filed voluntarily petitions for Chapter 11 bankruptcy.
Via
Benzinga
Earnings Preview: Atea Pharmaceuticals
May 05, 2023
Via
Benzinga
Preview: Atea Pharmaceuticals's Earnings
February 27, 2023
Via
Benzinga
Skyline Champion, Atea Pharmaceuticals And Other Big Stocks Moving Lower On Tuesday
May 30, 2023
U.S. stocks traded mixed, with the Dow Jones dropping over 100 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Atea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
May 30, 2023
Proposal Fundamentally Undervalues Atea; Not in the Best Interests of Atea or Its Shareholders
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
May 23, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Biotech Bargain Hunt: Concentra Biosciences Eyes Atea's Promising COVID-19 Response
May 22, 2023
Earlier today, Concentra Biosciences, an affiliate of Tang Capital, sent an acquisition proposal to Atea Pharmaceuticals Inc (NASDAQ: AVIR) at $5.75 per share, representing a 55% premium to Friday’s...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
May 22, 2023
Via
Benzinga
Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
May 22, 2023
Gainers Greenhill & Co., Inc. (NYSE: GHL) shares jumped 116.4% to $14.67 after Mizuho announced it would acquire the company for $15 per share.
Via
Benzinga
Atea Pharmaceuticals Inc. (NASDAQ: AVIR) Highlighted for Surprising Price Action
May 22, 2023
Via
Investor Brand Network
Exposures
COVID-19
US Stocks Mixed; Nordic American Tankers Posts Upbeat Results
May 22, 2023
U.S. stocks traded mixed this morning, with the Dow Jones trading slightly lower on Monday. Following the market opening Monday, the Dow traded down 0.01% to 33,422.94 while the NASDAQ rose 0.09% to...
Via
Benzinga
Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
May 08, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023
May 01, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19
April 25, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases
April 12, 2023
71% reduction in risk of hospitalization for mild to moderate COVID-19 outpatients treated with bemnifosbuvir versus placebo in MORNINGSKY study, regardless of vaccination status
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research
March 14, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research
March 08, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 28, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023
February 23, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
February 21, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
February 28, 2023
During Tuesday, 79 stocks hit new 52-week lows.
Via
Benzinga
Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic Infections
February 15, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
February 15, 2023
On Wednesday, 35 stocks hit new 52-week lows.
Via
Benzinga
Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
February 07, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Highlights Strategic Priorities for 2023
January 09, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19
November 29, 2022
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 22, 2022
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Atea Pharmaceuticals to Present at the Jefferies London Healthcare Conference
November 08, 2022
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.